Genmab — April 2018
-
Dara+actinium og dara+SGN-CD48A http://www.abstractsonline.com/pp8/#!/4562/presentation/9725 http://www.abstractsonline.com/pp8/#!/4562/presentation/8409
-
JNJ-61186372 (altså EFGR/cMET) er blevet udvidet til 190 patienter. Det er mere end en fordobling af den oprindelige plan. Aktiv rekruttering udvidet med en klinik mere i USA og flere på vej. https://clinicaltrials.gov/ct2/show/record/NCT02609776?term=jnj+bispecific&rank=1
-
ADCT-301 er også med på AACR, hvor de tilsyneladende har gjort nye opdagelser i præklinikken, som ikke har været fremme før. http://www.abstractsonline.com/pp8/#!/4562/presentation/4169
-
Konklusionen fra ADC Therapeutics hjemmeside: Novel data identifies CD25 as a previously unrecognized feedback regulator of oncogenic B/TCR-signaling supporting CD25 as a therapeutic target in refractory lymphoid malignancies.
ADCT-301 demonstrated durable remissions in patient-derived Ph+ALL cells PDX models http://adctherapeutics.com/ -
Det var jo fine kliniske data, de præsenterede for Cami-T på ASH - især i Lymphoma - https://adcreview.com/tag/camidanlumab-tesirine/ og som jeg forstår det, mener de nu, at ved at blokere for signalveje, der udgår fra CD25, opnås yderligere effekt ved selve CD25-antistoffet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind